Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Price Performance

Shares of Pulmatrix stock opened at $6.40 on Friday. Pulmatrix has a 1 year low of $1.55 and a 1 year high of $8.44. The firm has a market cap of $23.37 million, a PE ratio of -2.42 and a beta of 1.54. The company has a 50 day simple moving average of $4.69 and a two-hundred day simple moving average of $2.99.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.